2026第95届武汉生物医药供应链展|AI赋能医药全产业链智造升级发表时间:2026-09-30 05:19 2026第95届武汉生物医药供应链展|AI赋能医药全产业链智造升级 时间:2026 年 11 月 11–13 日 地点:武汉国际博览中心(武汉市汉阳区鹦鹉大道 619 号) 主办:国药励展展览有限责任公司 同期展:SINOPHEX 制药设备展、PHARMPACK 医药包装展、PHARMEX 药用辅料展主题:科技引领・匠心智造・链通全球 展会规模 展览面积约 80000㎡,2000 + 海内外展商,预计12 万 + 专业观众,覆盖全球 30 多个国家与地区,汇聚 300 余家行业龙头企业。 展品范围(生物医药供应链全链条) 原料药 & 中间体:化学原料药、生物原料药、医药中间体、天然提取物、精细医药化工原料 药用辅料:制剂辅料、功能性辅料、包材辅料 医药包装(PHARMPACK):药用玻璃、橡胶塞、铝塑复合膜、预灌封注射器、药用包装材料 制药设备(SINOPHEX):原料药设备、制剂设备、净化设备、检测仪器、自动化产线 生物医药研发供应链:CRO/CDMO/CMO 外包服务、生物试剂、实验室耗材、质量检测、环保技术 大会黄金展位预定请咨询:谢经理18616981016(同微信)
在全球生物医药产业链加速重构、国内产业迈向数字化、国产化、高端化的关键节点,依托中部医药产业核心区位优势,2026年第95届中国国际武汉生物医药供应链展(API China 2026 Wuhan)将于11月11日-13日重磅落地武汉国际博览中心。作为亚太地区极具影响力的医药供应链标杆展会,本次盛会以“科技引领·匠心智造·链通全球”为核心主题,聚焦AI赋能智造、供应链安全、创新药产业化等行业前沿赛道,全力打通中部医药产业内外循环壁垒,为国内外医药企业搭建商贸对接、技术革新、资源整合的一体化高端平台。 Against the backdrop of global biomedical industrial chain restructuring and China’s pharmaceutical industry upgrading toward localization and digitalization, the 95th China International Wuhan Biomedical Supply Chain Exhibition (API China 2026 Wuhan) will grandly open at Wuhan International Expo Center. Rooted in the central China pharmaceutical industrial cluster, the exhibition focuses on core industry hotspots including AI intelligent manufacturing, supply chain security and innovative drug industrialization, building a full-link cooperation platform for global pharmaceutical enterprises. 2026年是国内生物医药供应链提质升级的关键之年,随着“人工智能+”行动深度落地,AI、物联网技术正全面渗透医药研发、生产、质控、流通全链条,彻底重塑传统医药产业模式。同时,国内创新药出海势头持续强劲,上半年创新药BD出海交易规模再创新高,国产化替代、全球化布局成为行业核心发展趋势。本次展会精准契合行业发展风口,打破传统医药展会单一展示模式,聚焦全产业链协同升级,覆盖原料药、医药中间体、药用辅料、医药包装、智能制药设备、CRO/CDMO研发外包、生物实验室耗材等全品类供应链板块,实现从源头原料到终端制剂、从智能生产到创新研发的全域覆盖。
In 2026, China’s biomedical industry is ushering in a critical period of industrial upgrading. Empowered by AI and IoT technology, the pharmaceutical supply chain has realized full-scene intelligent iteration from R&D and production to quality control and circulation. Driven by the booming overseas export of innovative drugs, the 95th API China Wuhan exhibition accurately grasps industry trends, covering the entire biomedical supply chain and realizing integrated display and docking of raw materials, packaging, equipment and R&D services. 相较于往届展会,本届武汉站展会实现多重创新升级。展会总展览面积扩容至80000㎡,汇聚2000+海内外优质展商,囊括300余家国内外医药行业龙头企业,预计吸引全球30多个国家和地区的12万+专业观众到场对接采购。展会深度立足中部地区医药产业集群优势,针对性解决行业供应链碎片化、供需匹配低效、高端技术壁垒等痛点,重点展示智能制药生产线、绿色化工中间体、高端药用包材、AI质控检测设备、一体化CDMO定制服务等前沿产品与技术,助力企业降本增效、突破技术瓶颈、拓宽海内外市场。 Compared with previous sessions, the 2026 Wuhan exhibition has achieved comprehensive upgrading in scale and content. With an exhibition area of 80,000 square meters, it gathers over 2,000 domestic and overseas exhibitors and attracts more than 120,000 professional visitors. Focusing on industry pain points such as fragmented supply chains and insufficient technical innovation, the exhibition displays cutting-edge products and technologies in intelligent pharmaceutical production, green raw materials and digital quality control, empowering enterprises to enhance core competitiveness. 为深化产业赋能价值,本次展会同步联动多场高端行业论坛、技术发布会、供需精准对接会,围绕医药供应链安全、创新药产业化、AI医药智造、药品合规生产、跨境商贸合作等热门议题展开深度研讨。汇聚行业专家、企业高管、科研机构代表,分享前沿政策动态、技术成果与市场趋势,搭建“技术交流+资源对接+商机转化”的立体化产业服务体系,助力中部生物医药产业集群迭代升级,推动国内医药供应链高质量、自主化、全球化发展。
The exhibition will simultaneously hold a series of high-end industry forums and precise supply-demand docking meetings, focusing on hot topics such as pharmaceutical supply chain security, innovative drug industrialization and AI intelligent manufacturing. It gathers industry experts and enterprise elites to share policy trends and technological achievements, building a three-dimensional industrial service system for technological exchange and business transformation. 深耕医药供应链领域五十余载,API China始终以链接产业资源、赋能行业发展为核心使命,历经94届沉淀,已成为亚太医药行业公认的“产业风向标”。2026武汉站展会立足中部、辐射全国、链接全球,将进一步激活华中医药产业活力,打通上下游产业链堵点,为国内医药企业国产化替代、全球化布局注入全新动能,助力中国生物医药产业在全球竞争中抢占新高地。 With more than 50 years of industry accumulation, API China has become a benchmark event in the Asia-Pacific pharmaceutical industry. The 2026 Wuhan session will further activate the vitality of the central China biomedical industry, smooth the upstream and downstream industrial chain, and inject new momentum for Chinese pharmaceutical enterprises to realize localized substitution and global layout. |